Core Viewpoint - Inotiv, Inc. has reported a cybersecurity incident that occurred in early August 2025, involving unauthorized access to its systems and potential acquisition of personal data [1][2][3]. Incident Details - The unusual activity was detected on August 5, 2025, leading to an investigation that confirmed unauthorized actions by a threat actor by August 8, 2025 [3][4]. - The investigation revealed that personal information may have been acquired, including names, Social Security numbers, financial account information, and health-related data [5][6]. Response Actions - Inotiv took immediate steps to contain the incident, launched an investigation with external cybersecurity specialists, and notified regulators and law enforcement [6][7]. - The company has informed affected individuals via mail and email and is offering complimentary credit monitoring services [7][8]. Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, aiming to enhance efficiency and reduce costs in bringing new drugs and medical devices to market [10][11].

Core Insights - Inotiv achieved a remarkable revenue growth of 448% from fiscal year 2021 to fiscal year 2024, earning a spot at 182 on the Deloitte Technology Fast 500™ ranking [1][2] - The company's success is attributed to its client-focused approach, strategic acquisitions, and the development of complementary services that enhance client support [2] - Inotiv has been recognized as a Deloitte Technology Fast 500™ winner for three consecutive years, reflecting both client trust and team dedication [2] Company Overview - Inotiv, Inc. is a leading contract research organization that provides nonclinical and analytical drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs and medical devices to market [5] - The company aims to support researchers in realizing the full potential of their critical research and development projects, contributing to a healthier and safer world [5] Industry Context - The Deloitte Technology Fast 500™ ranks the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America based on percentage revenue growth [3] - The 2025 rankings highlight a mix of established leaders and new innovators, with private companies showing significant agility and growth potential in competitive markets [2][3]

Company Overview - Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, as well as research models and related products [3] - The company's focus is on enhancing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [3] - Inotiv aims to support discovery and development objectives while contributing to a healthier and safer world [3] Upcoming Event - Robert Leasure Jr., President and CEO of Inotiv, will present at the Jefferies Global Healthcare Conference in New York on June 4 at 3:45 p.m. ET [1] - The live webcast of the presentation will be available in the "Investors" section of Inotiv's website and will be archived for approximately 90 days [2]